ADCs: Opportunities And Challenges For Chinese Companies

Industry experts gathered recently to discuss China’s influential role in today’s antibody-drug conjugate (ADC) R&D space. Tap into the key highlights from this discussion, which traced China’s emergence as an important R&D hub, the challenges facing China’s ADC-focused biotechs, and the opportunities that may soon lie ahead for ADC therapies.

Download the summary now to explore:

How China has grown in importance as an ADC R&D hub
What gives China a significant advantage as a development center for ADC therapies
Which pain points in commercialization are being felt most acutely by China’s ADC developers
How CROs are helping China’s ADC developers navigate critical challenges
What lies ahead and how China can overcome obstacles in commercialization, regulatory, and technology

Download for the Summary

Your Company Email Address

Opt In?

By completing this form you agree Citeline and Novotech Pty Limited may store and process your personal data as well as contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Citeline and Novotech Pty Limited.